What question did this study set out to answer?

To evaluate the prognostic value of the PSA Kelim Score in high-volume mCSPC patients treated with ARPI.

April 18, 2026Open Access

Prognostic value of PSA kelim score in high-volume mCSPC patients treated with abiraterone or enzalutamide: a single-center retrospective study

Key Points

To evaluate the prognostic value of the PSA Kelim Score in high-volume mCSPC patients treated with ARPI.
Retrospective analysis at a single center
Assessment of PSA Kelim Score
Comparison of outcomes based on PSA decline
Early PSA decline (Kelim < 1) correlates with improved outcomes
The PSA Kelim Score may guide treatment adjustments
Outcomes are similar regardless of ARPI type

Abstract

The PSA Kelim Score seems to be a promising and practical prognostic biomarker in high-volume mCSPC. Early PSA decline (Kelim < 1) correlates with better outcomes, regardless of ARPI type. Incorporating it into clinical decision-making may allow for timely treatment adjustments. Prospective validation is needed.

Bookmark

View Full Paper

Bookmark

View Full Paper

Prognostic value of PSA kelim score in high-volume mCSPC patients treated with abiraterone or enzalutamide: a single-center retrospective study

Key Points

Abstract

Cite This Study